Liraglutide for the treatment of type 2 diabetes mellitus
NICE recommends liraglutide taken at a dose of 1.2mg once a day as a possible treatment for some people with type 2 diabetes mellitus. However, NICE does not recommend liraglutide taken at a higher dose of 1.8mg once a day (NICE)
Effect of pharmacist-led patient education on glycemic control of type 2 diabetics
This study demonstrates an improvement in diabetes management of type 2 diabetics by involving a pharmacist in the multidisciplinary teams in the outpatient clinics – full PDF (Journal of Research in Medical Sciences)
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes
Addition of 2 µg/day paricalcitol to RAAS inhibition safely lowers residual albuminuria in patients with diabetic nephropathy, and could be a novel approach to lower residual renal risk in diabetes (The Lancet)
An Understanding of the Lack of Efficacy of Aspirin in Peripheral Arterial Disease (PAD) and Diabetic Patients
However, although antiplatelet therapy with low-dose aspirin has been reported to prevent vascular events in high-risk patients with cardiovascular disease, recent studies in patients with PAD or diabetes mellitus have failed to support the efficacy of aspirin in preventing vascular events in these patient populations (PubMed)
Multivitamins, individual vitamin and mineral supplements, and risk of diabetes mellitus among older U.S. adults
In this large cohort of U.S. older adults, multivitamin use was not associated with diabetes risk. The findings of lower diabetes risk among frequent users of vitamin C or calcium supplements warrant further evaluations (Diabetes Care)
Self-management problem solving for adolescents with type 1 diabetes
Intervention processes associated with an Internet program (Patient Education and Counseling)
The importance of measuring self-efficacy in patients with diabetes
Self-efficacy impacts adherence to treatment and therefore plays a role in the clinical outcome. The practical implication is that assessment of self-efficacy in people with diabetes may be a first step in the development of individually tailored interventions (Family Practice)
The changing epidemiology of type 1 diabetes: why is it going through the roof?
This review summarizes current research efforts directed at understanding the possible reasons for this increase, including the role of viruses, gut microbiota, early life feeding patterns, perinatal factors and childhood growth patterns. It also provides a road map for future research directions (Diabetes/Metabolism Research and Reviews)
Glycemic Thresholds for Diabetes-Specific Retinopathy: Implications for Diagnostic Criteria for Diabetes
This study broadens the evidence-base on diabetes diagnostic criteria. A narrow threshold range for diabetes-specific retinopathy was identified for FPG and HbA1c but not for 2-h PG. The combined analyses suggest that the current diabetes diagnostic level for FPG could be lowered to 6.5 mmol/L and that an HbA1c of 6.5% is a suitable alternative diagnostic criterion (Diabetes Care)
FDA Issues Complete Response Letter to Biodel Regarding New Drug Application for Linjeta
The U.S. Food and Drug Administration has issued a Complete Response Letter requesting additional information regarding the company’s new drug application for Linjeta™ (human insulin [rDNA origin]) injection 100IU/mL for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control (PharmaLive)
Peroxynitrite Mediates Diabetes-Induced Endothelial Dysfunction: Possible Role of Rho Kinase Activation
We propose that FeTPPs improves diabetes-induced endothelial dysfunction through reducing peroxynitrite formation and restoring eNOS expression and hence increases NO production and availability (Experimental Diabetes Research)
IDF Centres of Education
IDF has launched a targeted Call for Applications for Centres of Education (International Diabetes federation)
Diabetes 2.0 Online!
This year the Diabetes Research Institute and Foundation are bringing you the latest news from the lab — online! (DRI)
Sponsorship appeal for 2011
The editorial team of Glycosmedia would welcome offers of sponsorship to help fund the publication of this free diabetes news bulletin during 2011. From January 2011 (as part of the sponsorship deal) it will be possible to feed the Glycosmedia diabetes news listing directly into your website. For further information please contact jim@glycosmedia.com
Glycosmedia is also available as an App: